Biotin
High dose biotin has been suggested to improve mitochondrial energy failure and contribute to myelin synthesis. In 5 French MS centres, 579 progressive MS patients were treated with high dose biotin (203 with PPMS and 376 with SPMS) [1]. The mean EDSS at baseline was 6.4; mean duration of biotin therapy was 12.7 years. EDSS improved in 72 patients (12.4%) and worsened in 110 (18.9%). There was no statistically significant difference between SPMS and PPMS patients. The reported EDSS improvement is remarkably similar to that seen in a previous phase 3 trial, where it was 12.6% [4].
Results from the open-label phase of the 12-months double-blind MS-SPI study at 4 years of follow-up showed that biotin was well-tolerated [5]. There were no new safety signals in the extension phase. Delayed biotin treatment resulted in higher disability over time. Patients improved after switching from placebo to biotin, and the effects of biotin observed in the double-blind phase were sustained over time [6]. After 9 and 12 months, the mean change in EDSS was statistically significant in favour of biotin vs placebo (see Figure).
Figure: Effect of biotin treatment on disability score [6]
Ocrelizumab
This monoclonal antibody depletes CD20 positive B lymphocytes. The ORATORIO trial investigated the effects of ocrelizumab in primary progressive MS. It showed consistent and sustained benefit of ocrelizumab over 5.5 years in measures of disability progression: Confirmed Disability Progression (CDP), Timed 25-Foot Walk Test (T25FW), 9-Hole Peg Test (9HPT), and a composite measure of CDP (cCDP) [2]. Treatment benefit in the ORATORIO open-label extension was consistent with that seen in the double-blind period and was maintained across different time points, indicating sustained benefit. The proportion of patients with time to onset of 48-week CDP (CDP48) was lower in the continuous ocrelizumab group versus those who switched from placebo to ocrelizumab; at week 168 (30.5% vs 44.4%; P<0.001), at week 192 (34.8% vs 48.5%; P<0.001), and at week 264 (43.7% vs 53.1%; P=0.03). Ocrelizumab had a more profound effect on CDP48 than after 12 and 24 weeks, potentially due to higher specificity for permanent disability accumulation.
Ibudilast
The phosphodiesterase inhibitor ibudilast is thought to act by diminishing proinflammatory cytokine production. Because little is known about whether PPMS and SPMS differ in terms of treatment response, a post-hoc analysis of SPRINT-MS was performed [3]. In the original randomised trial, the effect of ibudilast on brain measures of integrity was evaluated in both PPMS (n=134) and SPMS (n=121) [7]. There was a marginally significant 3-way interaction between the treatment effect and disease course (P=0.0576), said Dr Andrew Goodman (University of Rochester School of Medicine and Dentistry, USA), who presented the results. The overall treatment effect was primarily driven by patients with PPMS (P=0.005), not by patients with SPMS (P=0.97). Dr Goodman suggested this difference may at least in part be explained by faster atrophy progression in the untreated PPMS patients (placebo group) than in the untreated SPMS patients (P=0.016). Backwards selection retained age, T2 lesion volume, retinal nerve fibre layer thickness, and longitudinal diffusivity as significant baseline covariates. However, the adjusted difference in treatment effect was still marginally significant (P=0.0715) and driven by PPMS (P=0.007).
Two other subanalyses of the SPRINT-MS trial were presented. One showed that ibudilast slowed annual macular volume loss over 96 weeks compared to placebo [8]. The other made clear that ibudilast treatment was not associated with a decline in either serum or CSF neurofilament light [9]. The authors speculated that inflammatory activity may have confounded the intended use of neurofilament light to measure neurodegeneration.
1. Moreau T, et al. AAN 2019, P3.2-083.
2. Wolinsky JS, et al. AAN 2019, P3.2-031.
3. Goodman A, et al. AAN 2019, S12.007.
4. Tourbah A, et al. Mult Scler. 2016;22(13):1719-31.
5. De Seze, et al. AAN 2019, P3.2-043.
6. De Seze, et al. AAN 2019, P3.2-063.
7. Fox RJ, et al. N Engl J Med 2018;379:846-55.
8. Bermel R, et al. AAN 2019, P3.2-049.
9. Fox R, et al. AAN 2019, P3.2-033.
Posted on
Previous Article
« New formulation of rimegepant: fast onset of action Next Article
Experimental Parkinsonās disease therapies »
« New formulation of rimegepant: fast onset of action Next Article
Experimental Parkinsonās disease therapies »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinsonās Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
Updates on three treatments of spinal muscular atrophy
July 30, 2019
Lasmiditan: rapid onset of efficacy in acute migraine
July 30, 2019
Interview with Prof. Natalia Rost
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy